home / stock / ampe / ampe news

AMPE News and Press, Ampio Pharmaceuticals Inc. From 12/19/19

Stock Information
Company Name: Ampio Pharmaceuticals Inc.
Stock Symbol: AMPE
Market: OTC
Website: ampiopharma.com
Menu
AMPE AMPE Quote AMPE Short AMPE News AMPE Articles AMPE Message Board
Get AMPE Alerts

News, Short Squeeze, Breakout and More Instantly...
AMPE - Barclays sees 21% upside in J&J in premarket analyst action

Aimmune Therapeutics (NASDAQ: AIMT ) initiated with Neutral rating and $33 (4% upside) price target at H.C. Wainwright. More news on: Aimmune Therapeutics, Inc., Ampio Pharmaceuticals, Inc., Apellis Pharmaceuticals, Inc., Healthcare stocks news, Stocks on the move, , Read more ...

AMPE - Ampio Provides Update on AP-013 Phase III Clinical Trial and Annual Meeting Conference Call Number

ENGLEWOOD, Colo. , Dec. 4, 2019 /PRNewswire/ -- Ampio Pharmaceuticals, Inc. (NYSE American: AMPE) a   development stage biopharmaceutical company, executing a Special Protocol Assessment (SPA) Phase III clinical trial titled  "Evaluating the Efficacy and Safety of Ampi...

AMPE - Ampio execs subpoenaed over alleged insider trading

Ampio Pharmaceuticals (NYSEMKT: AMPE ) discloses ( 10-Q, page 23 ) that one of its directors received a subpoena from the SEC requesting documents and information related to its ongoing investigation into potential insider trading. More news on: Ampio Pharmaceuticals, Inc., Healthcare stoc...

AMPE - Ampio Provides Update on Continued Progress of AP-013 Phase III Clinical Trial and Manufacturing Facility

ENGLEWOOD, Colo. , Oct. 10, 2019 /PRNewswire/ -- Ampio Pharmaceuticals, Inc. (NYSE American: AMPE) a development stage biopharmaceutical company, executing a Special Protocol Assessment (SPA) Phase III clinical trial titled "Evaluating the Efficacy and Safety of Ampion TM to treat Adults...
AMPE - Ampio Retains Legal Counsel for Transaction Advisory Committee

ENGLEWOOD, Colo. , Sept. 18, 2019 /PRNewswire/ -- Ampio Pharmaceuticals, Inc. (NYSE American: AMPE) a development stage biopharmaceutical company, executing a Special Protocol Assessment (SPA) phase three clinical trial titled  "Evaluating the Efficacy and Safety of Ampion to tr...

AMPE - Ampio Pharma advancing late-stage study AP-003-A

Ampio Pharmaceuticals (NYSEMKT: AMPE ) is up  3%  premarket on the heels of an update on its Phase 3 study of AP-003-A in patients with knee osteoarthritis-related pain. More news on: Ampio Pharmaceuticals, Inc., Healthcare stocks news, Stocks on the move, Read more ...

AMPE - Ampio Pharmaceuticals Retains Financial Advisor and Appoints Transaction Advisory Committee

ENGLEWOOD, Colo. , Aug. 22, 2019 /PRNewswire/ -- Ampio Pharmaceuticals, Inc. (NYSE American: AMPE) a development stage biopharmaceutical company, executing a special protocol assessment (SPA) phase three clinical trial titled, "A Randomized, Controlled, Double-Blind Study to Evaluat...
AMPE - Ampio Pharmaceuticals Updates Progress of SPA Clinical Trial

ENGLEWOOD, Colo. , July 25, 2019 /PRNewswire/ -- Ampio Pharmaceuticals, Inc. (NYSE American: AMPE) today announced the progress to date in the Company's special protocol assessment (SPA) phase three clinical trial titled  "A Randomized, Controlled, Double-Blind Study to Evaluate...

AMPE - Ampio Appoints Moss Adams LLP as the Company's New Independent Auditor

ENGLEWOOD, Colo. , July 11, 2019 /PRNewswire/ -- Ampio Pharmaceuticals, Inc. (NYSE American: AMPE), a development stage biopharmaceutical company focused on the discovery and development of a novel therapy aimed at treating common inflammatory conditions for which there are limited t...

AMPE - Ampio Appoints Dan Stokely as the Company's new Chief Financial Officer

ENGLEWOOD, Colo. , July 10, 2019 /PRNewswire/ -- Ampio Pharmaceuticals, Inc. (NYSE American: AMPE), a development stage biopharmaceutical company focused on the discovery and development of a novel therapy aimed at treating common inflammatory conditions for which there are limited t...
Previous 10 Next 10